提供学术论文选刊润色服务
医学
医学
Paper Review Records
全部论文审稿周期
20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
49
天
Bayesian‐Estimated Vancomycin AUC24 as a Near‐Term Renal Risk Signal after Therapeutic Drug Monitoring: A Multicenter Cohort Study
作者Tran Van Anh; Bui Thi Tham; Tran Thi Ngan; Nguyen Duc Long,; Nguyen Huong Giang; Nguyen Hoang Anh; Vu Dinh Hoa; Hoang Van Dung; Nguyen Thi Thu Phuong
作者单位1. Faculty of Pharmacy Hai Phong University of Medicine and Pharmacy Hai Phong Viet Nam; 2. Department of Pharmacy Hai Phong International Hospital Hai Phong Viet Nam; 3. Hanoi University of Pharmacy Hanoi Viet Nam; 4. Vietnam National Drug Information and Adverse Drug Reaction Monitoring Centre Hanoi Viet Nam; 5. Department of Internal Medicine Hai Phong International Hospital Hai Phong Viet Nam; 6. Department of Internal Medicine Hai Phong University of Medicine and Pharmacy Hai Phong Viet Nam
59
天
Tamoxifen Therapy Is Associated With Altered Intestinal P‐Glycoprotein Activity In Vivo
作者Álef Machado Gomes Pego; Fernanda de Lima Moreira; Ana Flavia Mendes Batista; Adriana Rocha; Maria Paula Marques Pereira; Eduardo Barbosa Coelho; Jurandyr Moreira de Andrade; Geraldo Duarte; Vera Lucia Lanchote; João Paulo Bianchi Ximenez
作者单位1. School of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo Ribeirão Preto São Paulo Brazil; 2. Faculty of Pharmacy Federal University of Rio de Janeiro Rio de Janeiro Rio de Janeiro Brazil; 3. Ribeirão Preto Medical School University of São Paulo Ribeirão Preto São Paulo Brazil
69
天
PBPK Modeling of Esomeprazole to Support Adolescent Pharmacokinetic Extrapolation and Label Extension in Chinese Patients With Gastroesophageal Reflux Disease (GERD)
作者Yuwen Jin; Junjie Ding; Xiaohan Hua; Wei Duan; Mo Chen; Zhaohui Zhou; Ramesh V Pandherpur; Jin Dong; Sharma Pradeep; Peiming Ma; Weifeng Tang; Diansong Zhou
作者单位1. Clinical Pharmacology R&D China AstraZeneca Shanghai China; 2. Respiratory & Immunology R&D China AstraZeneca Shanghai China; 3. Biometrics and Data Science R&D China AstraZeneca Shanghai China; 4. Clinical Safety R&D China AstraZeneca Shanghai China; 5. Clinical Development BioPharmaceuticals R&D AstraZeneca Bengaluru India; 6. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Gaithersburg Maryland USA; 7. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Cambridge UK; 8. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Waltham Massachusetts USA
133
天
Safety, Tolerability, and Pharmacokinetics of Oral Camlipixant: A Randomized First‐In‐Human Study Using Single and Multiple Ascending Doses
作者Nathalie Chauret; Denis Garceau; Laurent Harvey; Zelie Bailes; Elizabeth A. Duncan; Rhian McNaughton; Miren Zamacona
作者单位1. Bellus Health Laval Quebec Canada; 2. GSK London UK; 3. GSK Durham North Carolina USA
73
天
Population Pharmacokinetics and Exposure–Response Analyses of Vepdegestrant, a First‐in‐Class PROteolysis‐TArgeting Chimera Estrogen Receptor Degrader
作者Derek Z. Yang; Joanna C. Masters; Hechuan Wang; Lana Tran; Yuanyuan Zhang; Kimberly C. Lee; Weiwei Tan; Brian Jermain
作者单位1. Pfizer Inc San Diego CA USA; 2. Arvinas Operations, Inc. New Haven CT USA; 3. Pfizer Inc Groton CT USA
114
天
FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease
作者Poonam R. Delvadia; Anantha Ram Nookala; Gopichand Gottipati; Sreedharan Sabarinath; Ramana S. Uppoor; Mehul U. Mehta; Xiulian Du; Yow‐Ming C. Wang; Milos Dokmanovic; Riley Myers; Jessica Stevens; Laura Baldassari; Paul Lee; Laura Jawidzik; Sandhya Apparaju; Suna Seo; Nina N. Brahme; Sarah J. Schrieber
作者单位1. Division of Neuropsychiatric Pharmacology Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 2. Therapeutic Biologics Program Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 3. Division of Product Quality Assessment XIII Office of Product Quality Assessment III Office of Pharmaceutical Quality Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 4. National Institute for Innovation in Manufacturing Biopharmaceuticals University of Delaware Newark DE USA; 5. Division of Neurology II Office of Neuroscience Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 6. Clintrex Research LLC A BlueRidge Life Sciences Company Houston TX USA; 7. Division of Gastroenterology Office of Immunology and Inflammation Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA; 8. Science Review Staff Office of Therapeutic Biologics and Biosimilars Office of New Drugs Center for Drug Evaluation and Research Food and Drug Administration Silver Spring MD USA
70
天
63
天
Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals
作者Paridhi Gupta; Ashish Sharma; Bernd Meibohm
作者单位1. Department of Pharmaceutical Sciences College of Pharmacy University of Tennessee Health Science Center Memphis TN USA; 2. Clinical Pharmacology Boehringer Ingelheim Pharmaceuticals Ridgefield CT USA
84
天
First‐in‐Human Study of a Long‐Acting GLP‐1 Receptor Agonist (TE‐8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus
作者Ya‐Shan Chuang; Jon D. Wright; Mun‐Teng Wong; Kushal J Paneliya; Wei‐Shiung Yang; Hsing‐Mao Chu; Tse Wen Chang; Thomas M Polasek
作者单位1. Immunwork, Inc. Taipei City Taiwan; 2. CMAX Clinical Research Pty Ltd Adelaide Australia; 3. Department of Internal Medicine National Taiwan University Hospital Taipei City Taiwan; 4. T‐E Meds, Inc. Taipei City Taiwan; 5. Centre for Medicine Use and Safety Monash University Melbourne Australia
203
天
An Open‐Label, 2‐Period, Fixed Sequence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder), with and without Concomitant Itraconazole in Healthy Adult Subjects
作者Detlef Albrecht; Elizabeth Hussey; Richard B. Lipton
作者单位1. Satsuma Pharmaceuticals Inc. Durham NC USA; 2. Allucent Cary NC USA; 3. Albert Einstein College of Medicine and Montefiore Headache Center Bronx NY USA
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿96.4 天
中位数77 天